In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii
Joon Young Song,Sae Yoon Kee,In Sook Hwang,Yu Bin Seo,Hye Won Jeong,Woo Joo Kim,Hee Jin Cheong +6 more
TLDR
Imipenem/sulbactam combination, colistin and tigecycline showed good in vitro activities against carbapenem-resistant A. baumannii, and the colist in/rifampicin combination is more warranted in order to be certain.Abstract:
Objectives: To determine the in vitro activities and interactions of imipenem, colistin and tigecycline with old antibacterial agents against carbapenem-resistant Acinetobacter baumannii. Methods: Forty-three carbapenem-resistant A. baumannli Isolates from the intensive care unit of a university hospital were collected and their MICs of imipenem, colistin and tigecycline were determined. With eight randomly selected carbapenem-resistant isolates, an in vitro time-kill study was performed for the evaluation of antibacterial activity of colistin, tigecycline, imipenem/sulbactam and colistin/ rifampicin. Results: The time-kill study of colistin demonstrated bactericidal activity against A. baumannii at concentrations of 4x MIC and 8x MIC, whereas tigecycline showed bacteriostatic activity at all concentrations. The combination regimens of imipenem/sulbactam and colistin/rifampicin were synergistic and bactericidal at 1 x MIC. Conclusions: Imipenem/sulbactam combination, colistin and tigecycline showed good In vitro activities against carbapenem-resistant A. baumannii isolates. Even though colistin is bactericidal against carbapenem-resistant A. baumannil, the colistin/rifampicin combination is more warranted in order to be certain.read more
Citations
More filters
Journal ArticleDOI
Acinetobacter baumannii: Emergence of a Successful Pathogen
TL;DR: This review details the significant advances that have been made in understanding of this remarkable organism over the last 10 years, including current taxonomy and species identification, issues with susceptibility testing, mechanisms of antibiotic resistance, global epidemiology, clinical impact of infection, host-pathogen interactions, and infection control and therapeutic considerations.
Journal ArticleDOI
Current control and treatment of multidrug-resistant Acinetobacter baumannii infections
TL;DR: Clinical reports support their effectiveness and mitigate previous concerns for toxicity, and several issues regarding the optimum therapeutic choices for multidrug-resistant A baumannii infections need to be clarified by future research.
Journal ArticleDOI
Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options.
TL;DR: Treatment of carbapenem-resistant A. baumannii infection involves the use of combinations of last resort agents such as colistin and tigecycline, but the efficacy and safety of these approaches are yet to be defined.
Journal ArticleDOI
Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies
TL;DR: Microbiological studies suggest superiority of colistin combination treatment, which is in contrast to preliminary data from studies in humans, and there is an urgent need for appropriately designed and powered clinical trials addressing this apparently controversial situation.
Journal ArticleDOI
Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence
Drosos E. Karageorgopoulos,Theodore Kelesidis,Theodore Kelesidis,Iosif Kelesidis,Iosif Kelesidis,Matthew E. Falagas,Matthew E. Falagas +6 more
TL;DR: Tigecycline showed considerable, though not consistent, antimicrobial activity against MDR (including carbapenem-resistant) Acinetobacter spp.
References
More filters
Journal ArticleDOI
National Committee for Clinical Laboratory Standards.
TL;DR: Many members of the Academy of Pediatrics seem to be generally unaware of the fact that the Academy has participated for ten years in a very interesting and valuable organization, the National Committee for Clinical Laboratory Standards (NCCLS).
Journal ArticleDOI
Colistin: The Revival of Polymyxins for the Management of Multidrug-Resistant Gram-Negative Bacterial Infections
TL;DR: Recent studies of patients who received intravenous polymyxins for the treatment of serious P. aeruginosa and Acinetobacter baumannii infections of various types, including pneumonia, bacteremia, and urinary tract infections, have led to the conclusion that these antibiotics have acceptable effectiveness and considerably less toxicity than was reported in old studies.
Journal ArticleDOI
Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections
Jian Li,Roger L. Nation,John D. Turnidge,Robert W. Milne,Kingsley Coulthard,Kingsley Coulthard,Craig R Rayner,David L. Paterson +7 more
TL;DR: Recent progress in understanding the complex chemistry, pharmacokinetics, and pharmacodynamics of colistin, the interplay between these three aspects, and their effect on the clinical use of this important antibiotic are summarized.
Journal ArticleDOI
Mechanisms of Multidrug Resistance in Acinetobacter Species and Pseudomonas aeruginosa
Robert A. Bonomo,Dóra Szabó +1 more
TL;DR: In addition, diminished expression of outer membrane proteins, mutations in topoisomerases, and up-regulation of efflux pumps play an important part in antibiotic resistance as discussed by the authors. Unfortunately, the accumulation of multiple mechanisms of resistance leads to the development of multiply resistant or even "panresistant" strains.